These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 26848769)
1. A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts. Azad BB; Chatterjee S; Lesniak WG; Lisok A; Pullambhatla M; Bhujwalla ZM; Pomper MG; Nimmagadda S Oncotarget; 2016 Mar; 7(11):12344-58. PubMed ID: 26848769 [TBL] [Abstract][Full Text] [Related]
2. Targeted Imaging of the Atypical Chemokine Receptor 3 (ACKR3/CXCR7) in Human Cancer Xenografts. Behnam Azad B; Lisok A; Chatterjee S; Poirier JT; Pullambhatla M; Luker GD; Pomper MG; Nimmagadda S J Nucl Med; 2016 Jun; 57(6):981-8. PubMed ID: 26912435 [TBL] [Abstract][Full Text] [Related]
3. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Chatterjee S; Lesniak WG; Gabrielson M; Lisok A; Wharram B; Sysa-Shah P; Azad BB; Pomper MG; Nimmagadda S Oncotarget; 2016 Mar; 7(9):10215-27. PubMed ID: 26848870 [TBL] [Abstract][Full Text] [Related]
4. Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Li K; Tavaré R; Zettlitz KA; Mumenthaler SM; Mallick P; Zhou Y; Marks JD; Wu AM Mol Cancer Ther; 2014 Nov; 13(11):2607-17. PubMed ID: 25143449 [TBL] [Abstract][Full Text] [Related]
5. The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies. Zeglis BM; Lewis JS J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741890 [TBL] [Abstract][Full Text] [Related]
6. Preloading with Unlabeled CA19.9 Targeted Human Monoclonal Antibody Leads to Improved PET Imaging with Houghton JL; Abdel-Atti D; Scholz WW; Lewis JS Mol Pharm; 2017 Mar; 14(3):908-915. PubMed ID: 28191976 [TBL] [Abstract][Full Text] [Related]
7. Development and Evaluation of an Brickute D; Braga M; Kaliszczak MA; Barnes C; Lau D; Carroll L; Stevens E; Trousil S; Alam IS; Nguyen QD; Aboagye EO Mol Pharm; 2019 May; 16(5):2106-2117. PubMed ID: 30883140 [TBL] [Abstract][Full Text] [Related]
9. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis. Sharma SK; Sevak KK; Monette S; Carlin SD; Knight JC; Wuest FR; Sala E; Zeglis BM; Lewis JS J Nucl Med; 2016 May; 57(5):771-6. PubMed ID: 26837339 [TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100. Weiss ID; Jacobson O; Kiesewetter DO; Jacobus JP; Szajek LP; Chen X; Farber JM Mol Imaging Biol; 2012 Feb; 14(1):106-14. PubMed ID: 21347799 [TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of ⁸⁹Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model. Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T Nucl Med Commun; 2015 Mar; 36(3):286-94. PubMed ID: 25460304 [TBL] [Abstract][Full Text] [Related]
12. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418 [TBL] [Abstract][Full Text] [Related]
13. 131I-labeled monoclonal antibody targeting neuropilin receptor type-2 for tumor SPECT imaging. Chen L; Wang L; Yan J; Ma C; Lu J; Chen G; Chen S; Su F; Wang W; Su X Int J Oncol; 2017 Feb; 50(2):649-659. PubMed ID: 28000859 [TBL] [Abstract][Full Text] [Related]
14. Zr-89 Immuno-PET Targeting Ectopic ATP Synthase Enables In-Vivo Imaging of Tumor Angiogenesis. Park BN; Kim GH; Ko SA; Shin GH; Lee SJ; An YS; Yoon JK Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412537 [TBL] [Abstract][Full Text] [Related]
15. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. Aerts HJ; Dubois L; Perk L; Vermaelen P; van Dongen GA; Wouters BG; Lambin P J Nucl Med; 2009 Jan; 50(1):123-31. PubMed ID: 19091906 [TBL] [Abstract][Full Text] [Related]
16. ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer. Sun H; England CG; Hernandez R; Graves SA; Majewski RL; Kamkaew A; Jiang D; Barnhart TE; Yang Y; Cai W Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2169-2179. PubMed ID: 27342417 [TBL] [Abstract][Full Text] [Related]
17. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts. ter Weele EJ; Terwisscha van Scheltinga AG; Kosterink JG; Pot L; Vedelaar SR; Lamberts LE; Williams SP; Lub-de Hooge MN; de Vries EG Oncotarget; 2015 Dec; 6(39):42081-90. PubMed ID: 26536664 [TBL] [Abstract][Full Text] [Related]
18. Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT. Nimmagadda S; Pullambhatla M; Pomper MG J Nucl Med; 2009 Jul; 50(7):1124-30. PubMed ID: 19525448 [TBL] [Abstract][Full Text] [Related]
19. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Lee CH; Kakinuma T; Wang J; Zhang H; Palmer DC; Restifo NP; Hwang ST Mol Cancer Ther; 2006 Oct; 5(10):2592-9. PubMed ID: 17041104 [TBL] [Abstract][Full Text] [Related]
20. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. Darash-Yahana M; Pikarsky E; Abramovitch R; Zeira E; Pal B; Karplus R; Beider K; Avniel S; Kasem S; Galun E; Peled A FASEB J; 2004 Aug; 18(11):1240-2. PubMed ID: 15180966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]